Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

Following years of rotating treatments, Pepol and his family moved once more, this time to Virginia, to be close to their now ...

Dean Pepol is no stranger to prostate cancer.Prostate cancer is the second-leading type of cancer death in American men, and Pepol has experienced ...

Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have ...

As the Trump administration upends federal research, Mizzou aims to raise more than $1 billion to build an advanced nuclear reactor to accelerate production of key ingredients for cancer treatments.

Bruce Power first began commercially producing Lutetium-177 in 2022, following the construction of an isotope production system at the plant's Unit 7 reactor, making it the world's first commercial ...

Multiple caucus and government sources confirmed the gathering will be held in the Alberta capital days before the start of ...

A Department of Energy grant and state legislature appropriation expands a relationship Mizzou has on developing cancer treatments.

Novartis accelerates its protein degrader programmes by licensing a phase 3-ready prostate cancer candidate from Arvinas in a deal worth over $1 billion.

Trio of radiopharma financings this week, as Telix files $200m US IPO, ITM raises $202m in a private round, and AstraZeneca invests in CDMO Nucleus.

Zachary Klaassen interviews Neal Shore about a presentation on health-related quality of life outcomes from the PSMAfore trial. Dr. Shore explains that while the VISION trial established Pluvicto's™ ...

OPCO Targeted Radiopharmaceutical Therapies in Oncology Summit – Panel Discussions Date: Thursday, September 11, 2025 Location : New York, NY Panel : Challenging Market Leaders Pluvicto & Lutathera ...